Duncan Jason
Reporting owner on Forms 3, 4 and 5, CIK 1741553.
Duncan Jason reported on 1 issuer in 2 filings, the latest a Form 4 filed 2026-11-13.
Issuers
| Issuer | Roles in the latest filing | Filings | Last filed |
|---|---|---|---|
| ENGN · enGene Therapeutics Inc.CIK 1980845 | officer (Chief Legal & Admin Officer) | 2 | 2026-11-13 |
Transactions and holdings
Every row of the person's Forms 3, 4 and 5, newest first, with the price and the amount owned after the row as filed.
| Security | Date | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| ENGN · enGene Therapeutics Inc.Stock Option (Right to Buy), derivative | 2026-11-13 | A granted | +500,000 | $0 | 500,000 | Form 4 |
| ENGN · enGene Therapeutics Inc.No securities beneficially held, holding | 0 | Form 3 |
Filings
The person's Forms 3, 4 and 5, and any 13D or 13G naming it.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| Form 4 0001552781-26-000553 | enGene Therapeutics Inc. | 2026-11-13 | ||
| Form 3 0001552781-26-000552 | enGene Therapeutics Inc. | 2026-11-13 |